EUS Guided Celiac Neurolysis

Completed · Not applicable

Conditions studied: Pancreatic Cancer Pain

In brief

* Hypothesis: \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.

Key facts

Study ID

NCT01615653

Run by

Mayo Clinic

People needed

110

Starts

2009-09-01

Expected to finish

2015-06-01

Last updated by the study team

2017-07-25

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Unresectable pancreatic carcinoma (T4 or M1) or advanced T3 disease
• 2. Cytologic or histologic confirmation of pancreatic carcinoma
• 3. Abdominal pain (≥ 3 on NRS scale), ≥ 2 days/week, lasting ≥ 1 hour/ day, stable intensity for ≥ 7 days
• 4. EUS clinically indicated (for non-study purposes)

You may not qualify if…

• 1. Uncorrectable coagulopathy: (INR) > 1.5 and/or platelets < 50,000
• 2. Abdominal surgery within 1 month
• 3. Prior celiac plexus or ganglia neurolysis.
• 4. Initiation or modification in chemotherapy or radiotherapy within prior 7 days.
• 5. Direct tumor infiltration of the celiac trunk and/or celiac ganglia.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.